Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

AzurRx BioPharma Issues Letter to Shareholders

GlobeNewswire April 21, 2020

Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX)

GlobeNewswire April 20, 2020

AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product

GlobeNewswire April 16, 2020

AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020

Accesswire April 15, 2020

AzurRx Appoints Gregory Oakes to its Board of Directors

GlobeNewswire April 9, 2020

AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit)

GlobeNewswire April 1, 2020

AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th

Accesswire March 18, 2020

AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)

GlobeNewswire March 2, 2020

AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference

GlobeNewswire February 18, 2020

AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

GlobeNewswire January 13, 2020

AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

GlobeNewswire January 9, 2020

AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

GlobeNewswire January 6, 2020

AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

GlobeNewswire January 3, 2020

AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

GlobeNewswire November 14, 2019

AzurRx BioPharma CEO Issues Letter to Shareholders

GlobeNewswire October 22, 2019

AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

GlobeNewswire October 17, 2019

AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire October 15, 2019

AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

GlobeNewswire October 10, 2019

AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

GlobeNewswire September 25, 2019

AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 13, 2019